BAL
MCID: ACT216
MIFTS: 34

Acute Leukemia of Ambiguous Lineage (BAL) malady

Categories: Rare diseases, Blood diseases, Immune diseases, Cancer diseases

Aliases & Classifications for Acute Leukemia of Ambiguous Lineage

Aliases & Descriptions for Acute Leukemia of Ambiguous Lineage:

Name: Acute Leukemia of Ambiguous Lineage 50
Acute Undifferentiated Leukemia 56 52 69
Mixed Phenotype Acute Leukemia 50 69
Acute Biphenotypic Leukemia 50 69
Biphenotypic Acute Leukemia 50 29
Acute Leukemia of Indeterminate Lineage 50
Acute Leukemia of Undetermined Lineage 50
Undifferentiated Acute Leukemia 50
Mixed Lineage Acute Leukemia 50
Aml with Lymphoid Markers 50
All with Myeloid Markers 50
Hybrid Acute Leukemia 50
Bal 50

Classifications:



External Ids:

Orphanet 56 ORPHA98835
ICD10 via Orphanet 34 C95.0
UMLS via Orphanet 70 C0856823

Summaries for Acute Leukemia of Ambiguous Lineage

MalaCards based summary : Acute Leukemia of Ambiguous Lineage, also known as acute undifferentiated leukemia, is related to acute leukemia and acute biphenotypic leukemia. An important gene associated with Acute Leukemia of Ambiguous Lineage is KMT2A (Lysine Methyltransferase 2A), and among its related pathways/superpathways are Transcriptional misregulation in cancer and PKMTs methylate histone lysines. The drugs Methotrexate and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include myeloid, and related phenotype is Increased shRNA abundance (Z-score > 2).

Wikipedia : 71 Acute biphenotypic leukaemia is a form of leukaemia where the lineage is of both lymphoid and myeloid... more...

Related Diseases for Acute Leukemia of Ambiguous Lineage

Diseases related to Acute Leukemia of Ambiguous Lineage via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
id Related Disease Score Top Affiliating Genes
1 acute leukemia 30.6 KMT2A MPO
2 acute biphenotypic leukemia 12.3
3 idiopathic acute eosinophilic pneumonia 10.9
4 leukemia 10.4
5 mercury poisoning 10.1
6 pneumonia 10.1
7 adducted thumbs dundar type 10.0 KMT2A MPO
8 pulmonary sarcoidosis 10.0
9 neurofibromatosis 10.0 KMT2A MPO
10 asthma 10.0
11 adult respiratory distress syndrome 9.9 KMT2A MPO
12 pulmonary fibrosis 9.9
13 tetraploidy 9.9
14 myeloid leukemia 9.9
15 lymphoid leukemia 9.9
16 tumefactive multiple sclerosis 9.9
17 lung disease 9.9
18 bronchiolitis 9.9
19 bronchiolitis obliterans 9.9
20 lymphoma, small cleaved-cell, diffuse 9.8 KMT2A MPO
21 eosinophilic pneumonia 9.8
22 malignant testicular leydig cell tumor 9.8 ANPEP MPO
23 extrinsic allergic alveolitis 9.7
24 asbestosis 9.7
25 interstitial lung disease 9.7
26 tuberculosis 9.7
27 heavy metal poisoning 9.7
28 hyperphosphatasia with mental retardation syndrome 2 9.7 ANPEP KMT2A MPO
29 acute lymphocytic leukemia 9.7 ANPEP KMT2A MPO
30 bleeding disorder, platelet-type, 18 9.7 ANPEP KMT2A MPO
31 phosphoserine phosphatase deficiency 9.7 ANPEP KMT2A MPO
32 bronchitis 9.7
33 neuronitis 9.7
34 peritonitis 9.7
35 chronic beryllium disease 9.7
36 lung cancer 9.7
37 cryptogenic organizing pneumonia 9.7
38 cystic fibrosis 9.7
39 lymphoma 9.7
40 nonspecific interstitial pneumonia 9.7
41 aspergillosis 9.7
42 pulmonary tuberculosis 9.7
43 bronchiectasis 9.7
44 respiratory failure 9.7
45 pulmonary edema 9.7
46 beryllium disease 9.7
47 hemosiderosis 9.7
48 porphyria 9.7
49 cranioectodermal dysplasia 1 9.6 ANPEP KMT2A MPO
50 pulmonary emphysema 9.5

Graphical network of the top 20 diseases related to Acute Leukemia of Ambiguous Lineage:



Diseases related to Acute Leukemia of Ambiguous Lineage

Symptoms & Phenotypes for Acute Leukemia of Ambiguous Lineage

GenomeRNAi Phenotypes related to Acute Leukemia of Ambiguous Lineage according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.44 SET
2 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.44 SET
3 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.44 SET
4 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.44 KMT2A PTPA SET
5 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.44 SET
6 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.44 SET
7 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.44 KMT2A
8 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.44 PTPA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.44 KMT2A
10 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.44 SET
11 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.44 KMT2A

Drugs & Therapeutics for Acute Leukemia of Ambiguous Lineage

Drugs for Acute Leukemia of Ambiguous Lineage (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 3,Phase 1,Phase 2 1959-05-2, 59-05-2 126941
2
Tacrolimus Approved, Investigational Phase 3,Phase 2 104987-11-3 445643 439492
3
Mycophenolic acid Approved Phase 3,Phase 2 24280-93-1 446541
4
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2 128794-94-5 5281078
5
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
6
Benzocaine Approved Phase 3,Phase 2 1994-09-7, 94-09-7 2337
7
Ofloxacin Approved Phase 3 82419-36-1 4583
8
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
9
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 54575, 6560146 143
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
11 tannic acid Approved, Nutraceutical Phase 3,Phase 2
12 Folic Acid Antagonists Phase 3,Phase 1,Phase 2
13 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
14 Dermatologic Agents Phase 3,Phase 1,Phase 2
15 Vitamin B Complex Phase 3,Phase 1,Phase 2
16 Anti-Infective Agents Phase 3,Phase 1,Phase 2
17 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
18 Antimetabolites Phase 3,Phase 2,Phase 1
19 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
20 Antirheumatic Agents Phase 3,Phase 1,Phase 2
21 triamcinolone acetonide Phase 3
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
23 Triamcinolone diacetate Phase 3
24 Triamcinolone hexacetonide Phase 3
25 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
26 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
27 Calcineurin Inhibitors Phase 3,Phase 2
28 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
29 Cytochrome P-450 Enzyme Inhibitors Phase 3
30 Renal Agents Phase 3
31 Folate Nutraceutical Phase 3,Phase 1,Phase 2
32 Vitamin B9 Nutraceutical Phase 3,Phase 1,Phase 2
33
Cytarabine Approved, Investigational Phase 1, Phase 2 147-94-4 6253
34
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
35
Vidarabine Approved Phase 1, Phase 2 24356-66-9 32326 21704
36
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
37
Hydrocortisone Approved, Vet_approved Phase 2,Phase 1 50-23-7 5754 657311
38
Clofarabine Approved, Investigational Phase 2,Phase 1 123318-82-1 119182
39
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
40
Cyclosporine Approved, Investigational, Vet_approved Phase 2 79217-60-0, 59865-13-3 5284373 6435893
41
Mitoxantrone Approved, Investigational Phase 1, Phase 2 65271-80-9 4212
42
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
43
Idarubicin Approved Phase 2 58957-92-9 42890
44
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
45
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563
46
rituximab Approved Phase 2 174722-31-7 10201696
47
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
48
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
49
Mesna Approved Phase 2 3375-50-6 598
50
Everolimus Approved Phase 2 159351-69-6 6442177

Interventional clinical trials:

(show all 38)
id Name Status NCT ID Phase
1 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Recruiting NCT01951885 Phase 3
2 Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Active, not recruiting NCT01371656 Phase 3
3 Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00990249 Phase 2
4 Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed NCT00372619 Phase 1, Phase 2
5 A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids - Mixed Phenotype Acute Leukemia (MPAL) Recruiting NCT02135874 Phase 2
6 GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Recruiting NCT02799147 Phase 1, Phase 2
7 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting NCT02728050 Phase 1, Phase 2
8 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Recruiting NCT02220985 Phase 2
9 Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes Recruiting NCT01690520 Phase 2
10 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Recruiting NCT02044796 Phase 1, Phase 2
11 Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting NCT01028716 Phase 2
12 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant Recruiting NCT00796068 Phase 2
13 Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease Recruiting NCT00719888 Phase 2
14 HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Recruiting NCT02793544 Phase 2
15 Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) Recruiting NCT02115295 Phase 2
16 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children Active, not recruiting NCT01858740 Phase 2
17 Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Not yet recruiting NCT02718755 Phase 2
18 Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Suspended NCT00723099 Phase 2
19 Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Terminated NCT02419755 Phase 2
20 Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed NCT02212561 Phase 1
21 Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia Completed NCT01132573 Phase 1
22 AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia Completed NCT01431664 Phase 1
23 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1
24 A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene Completed NCT02141828 Phase 1
25 S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia Recruiting NCT01925131 Phase 1
26 Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Recruiting NCT02879695 Phase 1
27 Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting NCT02921061 Phase 1
28 Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies Active, not recruiting NCT02270788 Phase 1
29 POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Active, not recruiting NCT01319864 Phase 1
30 Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) Not yet recruiting NCT02578511 Phase 1
31 Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia Terminated NCT01887587 Phase 1
32 Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Terminated NCT00933985 Phase 1
33 Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Recruiting NCT02828358
34 High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Recruiting NCT02551718
35 Matched Targeted Therapy For High-Risk Leukemias Recruiting NCT02670525
36 Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting NCT01701323
37 Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia Active, not recruiting NCT01804101
38 Acute Lymphoblastic Leukemia Registry at Asan Medical Center Terminated NCT01761682

Search NIH Clinical Center for Acute Leukemia of Ambiguous Lineage

Genetic Tests for Acute Leukemia of Ambiguous Lineage

Genetic tests related to Acute Leukemia of Ambiguous Lineage:

id Genetic test Affiliating Genes
1 Biphenotypic Acute Leukaemia 29

Anatomical Context for Acute Leukemia of Ambiguous Lineage

MalaCards organs/tissues related to Acute Leukemia of Ambiguous Lineage:

39
Myeloid

Publications for Acute Leukemia of Ambiguous Lineage

Articles related to Acute Leukemia of Ambiguous Lineage:

(show all 11)
id Title Authors Year
1
Acute Leukemia of Ambiguous Lineage in Elderly Patients - Analysis of Survival Using Surveillance Epidemiology and End Results-Medicare Database. ( 27998706 )
2016
2
A rare case of acute leukemia of ambiguous lineage overexpressing C-MYC with monosomy 7 and Philadelphia chromosome. ( 26159563 )
2015
3
Novel r(2)(p25q31) cytogenetic abnormality in a pediatric patient with acute leukemia of ambiguous lineage. ( 25436969 )
2015
4
Acute leukemia of ambiguous lineage with trisomy 4 as the sole cytogenetic abnormality: A case report and literature review. ( 24918064 )
2014
5
MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia. ( 23444217 )
2013
6
Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens. ( 23274355 )
2013
7
Two cases of near-tetraploidy in acute leukemias of ambiguous lineage. ( 24003431 )
2013
8
Case study interpretation--Portland: Case 4. Acute leukemia of ambiguous lineage, unclassifiable. ( 22431474 )
2012
9
Acute leukemia of ambiguous lineage, biphenotype, without CD34, TdT or TCR-rearrangement. ( 19687594 )
2009
10
Erythrophagocytosis in de novo-philadelphia-positive acute leukemia of ambiguous lineage. ( 16923527 )
2006
11
Hybrid chemotherapy in two children with acute leukemia of ambiguous lineage. ( 16411195 )
2006

Variations for Acute Leukemia of Ambiguous Lineage

Expression for Acute Leukemia of Ambiguous Lineage

Search GEO for disease gene expression data for Acute Leukemia of Ambiguous Lineage.

Pathways for Acute Leukemia of Ambiguous Lineage

Pathways related to Acute Leukemia of Ambiguous Lineage according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.51 KMT2A MPO
2
Show member pathways
11.31 KMT2A SET
3 11.02 ANPEP MPO
4 10.52 ANPEP MPO

GO Terms for Acute Leukemia of Ambiguous Lineage

Molecular functions related to Acute Leukemia of Ambiguous Lineage according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase regulator activity GO:0019888 8.62 PTPA SET

Sources for Acute Leukemia of Ambiguous Lineage

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....